Animal Blood Products Market

Animal Blood Products Market Summary:

As per the Transpire Insight Analysis, the Animal Blood Products Market size is estimated at USD 2.39 Billion in 2025 and is anticipated to reach USD 4.07 Billion by 2033, growing at a CAGR of 6.91% from 2026 to 2033.

Animal blood products-serum, plasma, immunoglobulins, and whole blood-are essential biological reagents used in vaccine manufacturing, cell culture, and veterinary use in transfusion and Diagnostics applications. While a structural shift toward serum- and animal component-free media has gained pace in the last 3-5 years due to regulatory pressures in EU and the growing debate over sourcing of fetal bovine serum (FBS) as shown in recent PubMed-reviewed literature, a realistic market trigger has been the regulatory approvals of serum free cultivated meat products in Singapore, Israel, UK markets that have proved viability and that reliance on FBS product is both market and ethically risky. While biologics production and superior veterinary treatment methods require traceability to and high-purity animal blood fractions, Biopharma R&D expenditure and Pet Humanisation are proportional to increased demand in serum and plasma, especially in North America and Europe with the highest clinical and regulatory needs.

Animal Blood Products Market Size & Forecast:

• Market Size 2025: USD 2.39 Billion
• Expected Market Value (2033): USD 4.07 Billion
• Forecast CAGR (2026–2033): 6.91%
• Leading Region in 2025: North America 
• Fastest Growing Region: Asia Pacific
• Key Company Profiles: Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, HiMedia Laboratories, GeminiBio, Cytiva, Rocky Mountain Biologicals, TCS Biosciences, PAN-Biotech, Lampire Biological Laboratories, Innovative Research, Serana Europe, Biowest, Atlas Biologicals, BioIVT.

Key Animal Blood Products Market Insights:

The animal blood products market is converging on traceable, GMP-grade fractions due to the increasing need for higher purity in biologics manufacturing and advanced veterinary care. The move towards serum-free alternatives is gaining speed due to ethical and regulatory concerns, especially in cell culture.

• Serum continues to dominate, at 34%, and Thermo Fisher Scientific has been ramping up GMP-grade FBS production to serve the biopharma market.
• Plasma is the largest segment, accounting for 24%, and the growth is attributed to Merck KGaA's investment in the extraction of immunoglobulin for vaccine platforms.
• Cell culture applications are expanding at a CAGR of 10.9% and are moving towards serum-free media, with BioIVT and PAN-Biotech introducing animal-component-free media.
• North America accounted for 39% of the market and is leading the market owing to the presence of well-established veterinary blood banks and biopharma infrastructure.
• Europe represents 30% and has a high degree of documentation of animal origin, which encourages suppliers to adopt better traceability systems.
• Asia Pacific accounts for 23% and is growing at a CAGR of 11.5%, with HiMedia Laboratories and GeminiBio growing their regional production.
• Bovine products are the most prevalent, and porcine and equine are growing in the speciality diagnostics area.
• Pharmaceutical companies are increasingly establishing direct sales channels, as they agree to long-term supply contracts for GMP-grade fractions.

What are the Key Drivers, Restraints, and Opportunities in the Animal Blood Products Market?

Driver:

“The engine of growth is expanding biologics manufacturing as well as sophisticated veterinary transfusion medicine.” This means the drivers behind the push include “greater spending on novel vaccine technologies and development of monoclonal antibodies, as they require both plasma and serum, often animal–sourced, to establish and grow cultures. More specifically, growth is driven by demand from biopharmaceutical companies entering supply contracts for GMP-grade plasma and serum, largely in the Americas and Europe.”

Restraint:

FBS collection ethical concerns and regulatory complexities continue to represent a systemic problem; European directives and additional US documentation requirements, especially for smaller suppliers lacking traceability systems, add complexity. Market access and increased operational costs can appear as barriers to new players entering the market.

Opportunity:

Chemically defined, serum-free media drive cultivation media for cultivated meat and regenerative medicine. Plant-based protein hydrolysates and microalgae extracts offer alternative solutions for animal-sourced FBS, with successful examples including Clear Meat and NouBio that commercialize scalable alternatives. Investment in these companies offers exposure to value creation from emerging, high-growth sectors with lower environmental and ethical concerns than traditional protein sourcing.

What Has the Impact of Artificial Intelligence Been on the Animal Blood Products Market?

These technologies are already utilized in streamlining blood product manufacturing and quality control. AI is now being applied, even on a small scale, toward prediction of transfusion requirements, assessment of bleeding risk, and optimization of inventory in veterinary blood banks. Through intelligent process monitoring for biologics, AI is assisting with real-time quality control of serum and plasma fractions in their manufacture, minimizing failed batches and improving the overall yield.

Deep learning, which improves diagnostics in immunohematology and blood typing, reduces the laboratory's turnaround time significantly. However, implementation is still hindered by the sheer cost of many of these systems and the shortcomings in data quality. Small biotech organizations and veterinary practices have a shortage of the necessary infrastructure for implementation, creating a potential lag in accuracy and use compared with large pharmaceutical companies. In biologics manufacturing, the regulatory landscape for AI is quite new. Guidelines for AI/ML in biologics are still in their infancy, with the vast majority of approvals for diagnostics rather than for process improvement and production applications. Thus, regulatory hurdles discourage investment in AI-enabled manufacturing and supply chain technologies by mid-tier suppliers.

In May 2026, Noul secured funding from the South Korean government's advanced medical device R&D program. This financial backing accelerates multinational pivotal studies for its automated AI blood analysis platform, aiming to expedite regulatory clearances.

https://www.koreabiomed.com/news/articleView.html?idxno=31716

Key Animal Blood Products Market Trends:

The market is transitioning from commodity sourcing of animal blood to controlled, documented, and application-specific animal blood inputs. Meanwhile, serum-free technologies are developing an alternative value chain, not just an alternative product, to the legacy one.

• The increase in cultivated meat adoption after 2023 regulatory approvals led to a reduction in FBS dependency, with the use of serum-free media increasing.
• Increased biopharma R&D spending drove up the demand for GMP-grade plasma and immunoglobulins in vaccine production.
• Veterinary transfusion medicine grew with the concept of pet humanization, leading to the use of whole blood and platelet concentrates.
• EU and US regulators stepped up documentation of animal origin, increasing compliance expenses for suppliers.
• The implementation of AI enhanced blood product manufacturing by optimizing inventory and quality control.
• Protein hydrolysates from plants became feasible FBS alternatives for cell culture applications.
• There was an increase in direct sales channels, with biopharma companies making long-term supply deals for traceable fractions.
• Research laboratories began to use animal-component-free media in line with ethical and regulatory requirements.

Animal Blood Products Market Segmentation

By Product Type:

Serum retains its top position at 34%, backed by research and cell-culture use; Plasma takes a strong 24% share, benefiting from processing into richer proteins. Whole Blood represents a smaller share of 15% and supplies veterinary, diagnostic, and R&D sectors; Immunoglobulins represent 12% in immune, as well as vaccine-specific areas; while cell-culture use accounts for 10%, and others fill the rest of the 5%. In general, movement to both defined and serum-free applications will strengthen those with a combination of tradition and tested alternatives in their portfolio.

By Animal Type:

Bovine products continue to hold primary business volumes due to existing collection infrastructure and the range of serum use. Porcine and Equine materials serve specific research, diagnostics, and veterinary purposes. Ovine and Poultry cater to the need to source for narrower species. Other segments are driven by application. A greater demand for origin documentation will increase multi-species sourcing and standardise specification qualification.

By Application:

The major areas for demand will be in Veterinary Medicine, Diagnostics and Research, & Vaccine production, and the strategic growth area will be Cell Culture with its CAGR of 10.9% as a move is being made to controlled media systems and reproducibility. Emerging areas of applications will rely on defined inputs and validated alternatives.

By End User:

The various needs for purchasing can be found in Research Laboratories & Universities, whereas Pharmaceutical & Biotechnology Companies are looking for GMP-grade, traceable fractions and Veterinary Hospitals are demanding blood-derived therapeutics. Agreements of supply over the long term are important to anchor qualified industrial suppliers.

By Distribution Channel:

Direct Sales becomes more important for the Pharma & Biotech-Customer that needs technical qualification, documents, and continuity. Laboratory suppliers and distributors are important for diffused requirements from research, and online sales are important for standard products. The future channel mix will see more direct online purchasing processes, with electronic documentation for the regulated sector.

What are the Key Use Cases Driving the Animal Blood Products Market?

Supplementing cell culture media during the manufacturing of biologics. These serum and plasma derivatives contain crucial growth factors required for vaccine and monoclonal antibody manufacturing. Pharmaceutical firms and research laboratories are the main drivers of demand, with the greatest markets in North America and Europe.

Additional applications include veterinary transfusion medicine, where whole blood and platelet concentrates are used in surgery and chronic condition treatments in companion animals; diagnostics; and immunohematology, with animal-derived immunoglobulins being utilized for blood typing and pathogen screening in immunohematology.

Potential future applications are cultivated meat production, shifting away from FBS into serum-free media, and regenerative medicine utilizing both human platelet lysates and animal component-free options.

Which Regions are Driving the Animal Blood Products Market Growth?

North America, accounting for 39% of revenues, is a dominant force thanks to its entrenched biologics manufacturing base, capable veterinary transfusion sector, and a healthy pre-existing regulatory environment. It contains some of the world's largest suppliers of GMP-grade serum and plasma fractions, including Thermo Fisher Scientific, Lampire Biological Laboratories, and Rocky Mountain Biologicals. High veterinary healthcare spending and the dog and cat humanisation trend result in high demand for whole blood and platelet concentrates.

Europe, with a 30% market share, is behind North America but remains resilient due to strict quality standards and sustainability principles. Europe's market growth is policy-driven; both EU Directive 2010/63/EU and documentation of animal origin represent additional barriers to uptake. Germany, the UK and France are the innovation centres for serum-free media and traceable blood fractions. This high level of regulation will support a resilient market in the long term but prevent rapid upscaling similar to North America.In January 2026, PromoCell launched a new range of human platelet lysate-derived serum-free media supplements. This product rollout accelerates animal-free compliance for European labs navigating strict regional mandates.

Asia Pacific has a 23% market share and 11.5% CAGR. This is the fastest-growing region, driven by increasing livestock production and escalating pet health spending. Recent developments include higher government spending on ag biotech and rejuvenation of veterinary hospital networks in India, China, and Southeast Asia. Regional production capacity is being increased by firms such as HiMedia Laboratories and GeminiBio to fulfil local demand. The key growth opportunities will be in cultivated meat and regenerative medicine, where serum-free media adoption is gaining momentum. In February 2026, GeminiBio partnered with Tolemy Bio to launch aiMOS. This collaboration introduced the first AI-enabled media optimization service to design custom serum-free supplements, improving performance, consistency, and scalability for advanced therapy and cell manufacturing.

Who are the Key Players in the Animal Blood Products Market, and how do they compete?

The animal blood products market is somewhat fragmented, with life sciences powerhouses fighting it out with specialist biologics companies. Competition seems to be based on GMP traceability, product purity, and geographical coverage, as end users look to ease regulatory controls and maintain supply.

Thermo Fisher Scientific and Merck KGaA are market leaders driven by innovation and vertical integration, providing complete solutions from blood collection to downstream manufacturing. Thermo Fisher is providing differentiation through its Orbitrap and Krios solutions as enabling tools for biologics manufacturing. Meanwhile, Merck benefits from its immunoglobulin extraction expertise to make vaccines. Both firms have grown through acquisition and long-term supply agreements with biopharma firms. Market players such as BioIVT, PAN-Biotech and HiMedia Laboratories offer specialised formulations and regional scalability. BioIVT and PAN-Biotech lead with animal-component-free serum-free media for cell culture, addressing ethical and regulatory concerns. HiMedia Laboratories and GeminiBio are competing on low-cost production in Asia Pacific, capturing burgeoning markets in key emerging markets. Lampire Biological Laboratories and Rocky Mountain Biologicals maintain differentiation with GMP-grade serum and plasma fractions for North American biopharma. TCS Biosciences and Serana Europe play into the regional European markets with traceable EU-compliant products.

Key Players are:

• Thermo Fisher Scientific
• Merck KgaA
• Bio-Rad Laboratories
• HiMedia Laboratories
• GeminiBio
• Cytiva
• Rocky Mountain Biologicals
• TCS Biosciences
• PAN-Biotech
• Lampire Biological Laboratories
• Innovative Research
• Serana Europe
• Biowest
• Atlas Biologicals
• BioIVT

Recent Development News

In June 2026, Pet Blood Bank UK announces the formal launch of its first-ever dedicated feline blood banking and transfusion service following official regulatory clearance from the Veterinary Medicines Directorate. This targeted product launch introduces structured, safety-tested feline blood components to the domestic veterinary market, addressing a critical critical-care gap for animal hospitals and specialized clinical networks.

Source: http://vettimes.com

In January 2026, Peru's National Agrarian Health Service (Senasa) authorizes four primary Brazilian processing facilities to officially export bovine and porcine blood-derived products into the Peruvian market. This regulatory milestone initiates active commercial shipments of animal blood products between the two countries, significantly scaling cross-border supply chain operations and expanding market access for South American agricultural processors.

Source: http://datamarnews.com

What Strategic Insights Define the Future of the Animal Blood Products Market?

The market is moving toward high-purity, traceable, serum-free alternatives and fractions due to the rapid growth of both biologics and cultivated meat manufacturing. A substantial, overlooked supply-chain risk exists in the form of regulatory fragmentation, in which varying animal-origin documentary requirements in Europe, the US, and Asia can lead to bottlenecks, longer times to market, and increased expenses in complying with local regulations. Simultaneously, emerging opportunities for scalable, ethical substitutes to fetal bovine serum (FBS) may lie in plant-derived protein hydrolysates and microalgal extracts in cell-based food manufacturing due to their potential for high-quality media. Companies should consider vertically integrating their own GMP-grade manufacturing facilities that can produce both FBS-derived media and serum-free alternatives to meet both current and future regulatory standards, enhance supply reliability, control product quality, and profit from expansion into both present-day and up-and-coming cell-based technologies like 3D printing, advanced biomanufacturing, regenerative medicine, and cultivated foods.

Key Segmentations are:

By Product Type

• Plasma
• Serum
• Whole Blood
• Immunoglobulins
• Albumin
• Others

By Animal Type

• Bovine
• Porcine
• Equine
• Ovine
• Poultry
• Others

By Application

• Veterinary Medicine
• Diagnostics Research
• Vaccine Production
• Cell Culture
• Others

By End User

• Research Laboratories
• Veterinary Hospitals
• Pharmaceutical Companies
• Biotechnology Companies
• Universities
• Others

By Distribution Channel

• Direct Sales
• Laboratory Suppliers
• Distributors
• Online Sales
• Others

Regional Outlook

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• Japan
• China
• Australia & New Zealand
• South Korea
• India
• Rest of Asia Pacific

South America

• Brazil
• Argentina
• Rest of South America

Middle East & Africa

• Saudi Arabia
• United Arab Emirates
• South Africa
• Rest of the Middle East & Africa